5 Reasons Why Moderna Stock Jumped 170% And How Far It Can Go

What Happened

Moderna became famous for its COVID vaccine five years ago, and its stock price is now at its highest since mid-2024. So, investors wasted no time taking profits after such a massive rally.

The post-announcement calls are much more useful.

Bank of America upgraded Moderna from Underperform to Neutral and increased its price target enormously, from $40 to $170. BofA described the result as a watershed event because it gives Moderna a credible route away from dependence on infectious-disease vaccines.

William Blair upgraded Moderna from Market Perform to Outperform, arguing that the Phase 3 result puts Moderna and Merck in position to seek regulatory approval and meaningfully changes Moderna’s diversification prospects.

So far Moderna and Merck have announced that the endpoints were achieved, without releasing the actual hazard ratios and detailed clinical data.

Market Context

Moderna (MRNA) jumped 177% on Wednesday, and the strangest part is how little news it took. A $200 million estimate change moved $30 billion on the stock market.

But can the stock price climb further? Or will the rally stop here?

The drug did not do it alone. Leerink’s revised estimate raised its 2032 sales estimate by roughly $200 million. Yet, the stock moved 150 times that amount in a market already at record highs.

The price sat above all six moving averages while analysts refused to believe with a $52.95 average target under the current price.

Moderna Stock Price Prediction: What Wall Street Giants Think

Morgan Stanley raised its target from $39 to $89, while keeping Equal Weight. Morgan Stanley now sees much greater value in Moderna’s scalable mRNA platform, but remains much more conservative on share price.

Brookline Capital: sets a target around $135, with a Buy rating.

That shows something important – even BofA’s extremely aggressive $170 target was below yesterday’s closing price.

Those detailed results are expected around the ESMO Congress in Madrid, October 23-27. That creates a natural trading window.

Why It Matters

The fundamental revaluation could last much longer. The next major event will likely be publication of the detailed Phase 3 numbers.

Details

What Actually Made Moderna Jump 130%?

Five loaded conditions did the rest. Moderna had collapsed 95% from $484 to $22. The recovery was already running, up 357% in 2026 on a flu approval before the cancer news.

And short sellers, traders who borrow shares and sell them betting on a fall, held 13.37% short interest in the freely traded shares, losing $4.8 billion when the readout forced them to buy back.

The Moderna move is one of those rare biotech events where the fundamental story genuinely changed overnight. The stock still overshot the immediate fundamentals, and today’s pullback is already showing that.

Ignore the old consensus target of roughly $50. Most of those targets were published before the Phase 3 result and are effectively obsolete.

So the fresh Street debate has suddenly become something like:

How Long Will the Moderna Stock Rally Last?

There are really two rallies. The short-squeeze/momentum rally probably peaked yesterday. Today’s roughly 20% drop is consistent with that. Once shorts have covered and momentum traders start taking profits, that mechanical buying disappears.

Analysts still want to see magnitude of benefit, overall-survival trends, safety details and manufacturing economics.